Skip to content

Investigating the effect of melatonin on memory impairment and oxidative stress biomarkers after ischemic stroke in patients admitted to the neurology department of Imam Khomeini Hospital in Urmia.

Investigating the effect of melatonin on memory impairment and oxidative stress biomarkers after ischemic stroke

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20241229064208N1
Enrollment
40
Registered
2025-01-20
Start date
2025-02-17
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke.

Interventions

Intervention 1: Intervention group: Melatonin 3 mg (one pill every night for two weeks),. Intervention 2: Control group:Placebo (one pill every night for two weeks).

Sponsors

Oroumia University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 18 to 80 years Informed consent will be obtained from individuals who are capable of completing the consent form themselves; otherwise, it will be obtained from their companions. Acute stroke incident that occurred within 7 days prior to admission Diagnosis of acute ischemic stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) at the time of admission Patients who have not received alteplase

Exclusion criteria

Exclusion criteria: No history of stroke Primary hemorrhagic stroke Pre-stroke diagnosis of cognitive decline or significant impairment A valid neurological disease in addition to stroke, such as Parkinson's disease Severe liver, kidney, or thyroid diseases, or heart failure, respiratory failure, or other organ failures Chronic inflammatory diseases, immune disorders, or hematologic disorders History of depression (clinical diagnosis or previous treatment) or other psychiatric disorders Severe visual impairment, inability to speak, or hearing impairment that may affect cognitive assessment. History of the use of nootropic or antipsychotic medications

Design outcomes

Primary

MeasureTime frame
Improvement Cognitive Impairment. Timepoint: Before and after the intervention. Method of measurement: Cognitive performance will be assessed using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) within 2 weeks after the stroke. The scores for MMSE and MoCA range from 0 to 30, with higher scores indicating better cognitive performance.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Rizvan Norouzzadeh

Oroumia University of Medical Sciences

norouzzade.r@umsu.ac.ir+98 44 3346 9931

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026